PCMO (Public CDMO for Microbial-based Vaccines) in Hwasun, Jeollanam-do (Director Min Cho) signed a Memorandum of Understanding (MOU) with BXPLANT (Co-CEOs Minkeun Jo and Heesun Kim) on the 3rd to establish collaboration across the full cycle of pharmaceutical development.
The key provisions of this agreement include sharing the latest trends in CDRO (Contract Development and Research Organization) and CDMO (Contract Development and Manufacturing Organization) industries, and building a collaborative network throughout the entire drug development process. BXPLANT plans to combine its CDRO services with PCMO’s manufacturing technology and production capabilities to accelerate the advancement of Korea’s bio industry and secure competitiveness in the global bio market.
BXPLANT provides CDRO services to domestic bio venture companies, offering full-cycle new drug development services from clinical development strategy establishment and early-stage R&D through preclinical and late-stage clinical trials. The company plans to actively support bio company growth as a scalerator, including company identification, investment attraction, and fundraising consulting.
PCMO is targeting completion of its mRNA vaccine manufacturing facility in the first half of 2025 and plans to strengthen its support for domestic pharmaceutical and bio companies based on experience accumulated through more than 100 projects to date. Since its establishment in 2017 with investment from the Ministry of Trade, Industry and Energy and Hwasun County, Jeollanam-do, PCMO has consistently supported the development of domestic vaccines and biopharmaceuticals.
Through this agreement, both organizations plan to build a collaborative network across the entire drug development process based on their respective expertise and expand technological innovation and growth potential in the bio sector. As global biotech companies have actively invested in the CDRO and CDMO markets in recent years, the future trajectory of these two organizations is highly anticipated.
BXPLANT Co-CEO Minkeun Jo stated, “Through collaboration with PCMO, we will combine CDRO services with manufacturing and production capabilities to elevate Korea’s bio industry to the next level and strengthen competitiveness in the global market. This MOU will be more than a simple business agreement—it will serve as an important starting point for accelerating growth in the bio ecosystem.”
source : PCMO and BXPLANT Sign MOU for Full-Cycle Drug Development Collaboration, Han-sik Kim, Electronic Times, 2024.12.05., https://www.etnews.com/20241205000461
